A trial showed that a combination can cure prostate cancer or prolong the life of a patient.
To treat patients with testosterone (ADT)
Together with abitron, the effect is stronger.
It is said that the new regime may "change" the treatment of 20,000 men diagnosed in the UK every year.
It can increase life expectancy from 3 years old.
For 5,000 people, the disease is in advanced stages in 5 to 7 years and has been transmitted around the body.
Most of the rest, only the pelvic areas have tumors and can survive as long as they do not have cancer.
The claim was filed after the trial of 1,900 men.
The average age at the beginning was 67.
Prostate cancer
Half were treated with hormone, a hormone, and the rest were treated with ADT plus abitron.
The mortality rate of both patients was 37 lower than that of patients only on the ADT.
The dual drug system reduces the risk of cancer deterioration by 71.
Professor Nicholas James, head of trials at the University of Birmingham, said: "This is the most powerful result I have seen from prostate cancer trials. It’s a once-in-a-career feeling.
Cancer Research UK said: "These results may change the treatment of prostate cancer.
"The British Association for prostate cancer welcomed the study and said it would urge the NHS to provide dual treatment.